Brepocitinib becomes first oral therapy approved for adult dermatomyositis
1. Brepocitinib is the first oral therapy specifically approved for adults with dermatomyositis, providing a disease-specific alternative to treatment strategies ...
Tag: dermatomyositis
2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...
Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...
#VisualAbstract: Intravenous immune globulin improved disease severity in dermatomyositis
1. Patients with dermatomyositis treated with intravenous immune globulin (IVIG) were more likely to see improvement in their disease severity ...
Intravenous immune globulin improved disease severity in dermatomyositis
1. Patients with dermatomyositis treated with intravenous immune globulin (IVIG) were more likely to see improvement in their disease severity ...
Clinical and epidemiological links with calcinosis in adult dermatomyositis
1. In adults with dermatomyositis (DM), calcinosis was positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibodies and ...
